CRISPR-based one-pot assay for the detection of monoclonal antibodies

Thumbnail Image
Del Giovane, Stefano
Migliorelli, Davide
Bagheri, Neda
Porchetta, Alessandro
Altug, Hatice
Burr, Loïc
Monoclonal antibodies (mAbs) are established therapies for malignancies, autoimmune and infection diseases. However, the administration of mAbs carries the risk of adverse effects and the development of resistance to the therapy by the production of anti-mAb antibodies. For these reasons, monitoring the serum concentration of the mAbs become crucial especially in cancer drug therapies. We present a novel Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based assay for mAbs detection that is simple to use and sensitive in the range of interest for the mAbs concentration in blood.
Publication Reference
NanoBioTech-Montreux Conference 2023